FirstWord

The companies will work together to develop medicines "across multiple therapeutic areas."

A pair of Phase III studies of OCS-01 eye drops failed to meet their primary endpoints, prompting the company to focus resources on its other late-stage assets.

Sevasemten, which works by limiting muscle damage caused by the absence or loss of functional dystrophin, is being developed for Becker and Duchenne muscular dystrophy.

Sonefpeglutide, which employs Hanmi's LAPSCOVERY platform technology, is currently in Phase II development for the treatment of short bowel syndrome-associated intestinal failure.

FirstWord rounded up the most notable late-breaking abstracts featuring potentially practice-changing results in lung, pancreatic and prostate cancers.

FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancerDetection of FT836 in the peripheral blood and tumor tissue illust...

Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor typesManageable tolerability confirmed across cohorts...

·One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and meta...

Clinically Meaningful Overall Antitumor Activity, with ORR of 42.9% and DCR of 95.9% across all evaluated dose levels in heavily pretreated patients.Enhanced Clinical Activity at the Recommended Phase...

Multiple confirmed partial and minor responses observed in patients with SGCContinuing very good safety profile, with removal of the lifetime maximum doxorubicin limit based on highly favorable cardia...